Immunologix has developed mAbLogix platform, which enables the ability to derive fully human antibodies.
The antibodies target all antigen types including, cancer cells, viruses, bacteria, toxins, as well as epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis.
Terms of the acquisition, however, have not been disclosed.